On Feb. 24, the biotech company said it had shipped the first batch of mRNA-1273 to the NIAID for clinical trials in the United States.
Patients will be closely monitored for one year. The trial will be held at Kaiser Permanente Washington Health Research Institute in Seattle, Wash.
Начали уже испытания в Сиэтле вакцины от короны ...
..короче, Яша ... ты там поспрашивавай, пару тройку доз почем ....
Bookmarks